PMS Registry
Company Name
Bayer Taiwan Co., Ltd.
Protocol Number
Title of Study
OPTIMIS - Outcomes of HCC patients treated with TACE followed or not followed by sorafenib and the
influence of timing to initiate sorafenib
Primary Objective
The primary objective of this study is the comparison of two cohorts of hepatocellular carcinoma patients regarding overall survival (OS) from time of TACE noneligibility.
The two cohorts of special interest are defined based on the investigators’ treatment decisions
(i.e. patients with early start of Sorafenib treatment vs. patients without early start of Sorafenib treatment).
Number of Sites
Period of Study
From:10/2013 to:07/2017
Number of Patients
IRB Approval Date
NTUH: Sep/30/2013
Publication Plan / Date